Development and in vitro evaluation of solid dispersions as strategy to improve albendazole biopharmaceutical behavior

CID, ALICIA GRACIELA; GONZO, ELIO EMILIO; SIMONAZZI, ANALÍA; SCHOFS, LAUREANO; BERMÚDEZ, JOSÉ MARÍA; PAREDES, ALEJANDRO JAVIER; PALMA, SANTIAGO DANIEL

Therapeutic Delivery

Future Medicine Ltd.

Lugar: NY; Año: 2018 vol. 9 p. 623 - 638

2041-5990

Aim: Solid dispersions using Poloxamer 407 as carrier were developed to improve albendazole (ABZ) solubility and dissolution profiles. Methods: ABZ/poloxamer solid dispersions were prepared, and dissolution profiles were mathematically modeled and compared with physical mixtures, pharmaceutical ABZ and a commercial formulation. Results: Poloxamer 407 increased exponentially ABZ solubility, in about 400% when 95% w/w of polymer compared with its absence. Solid dispersions initial dissolution rate was three to 20-fold higher than physical mixtures, the drug and the commercial formulation. All the solid dispersions required less than 2.2 min to reach an 80% of ABZ dissolution, while the commercial formulation needed around 40 min. Conclusion: Solid dispersions improved ABZ solubility and dissolution rate, which could result in a faster absorption and an increased bioavailability.